CC-93538

Phase 3Small molecule

Bristol-Myers Squibb

CC-93538 is one of 15 small molecule programs targeting Eosinophilic Esophagitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Eosinophilic EsophagitisActive, not recruiting

Eosinophilic EsophagitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Eosinophilic Esophagitis

#DrugCompanyPhaseTrials

Pulmicort

SSalix

Approved

12 2

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Approved

9 3

Flovent

PParatek Pharmaceuticals Inc

Approved

5 4

Prevacid

Takeda

Approved

—5

Flovent

PParatek Pharmaceuticals Inc

Approved

2 6

Prilosec

DDexcel Pharma Technologies Ltd.

Tezspire

1 8

Takecab

PPhathom Pharmaceuticals, Inc.

Phase 2

1 9

CC-93538

Bristol-Myers Squibb

Phase 3

2 10

Omeprazole BID

UUniversity of Colorado, Denver

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Eosinophilic Esophagitis

NCT04991935

Clinical

Trials by Indication[1]

Eosinophilic Esophagitis2 trials

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04753697·430 enrolled

Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04991935·368 enrolled

Atopic Dermatitis1 trial

A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT04800315·221 enrolled

Concentration1 trial

Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04373187·52 enrolled

Gastroenteritis1 trial

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Subjects With Eosinophilic Gastroenteritis

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT05214768·48 enrolled

Unspecified1 trial

Japanese Pharmacokinetic Bridging Study for CC-93538

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04096105·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for CC-93538. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CC-93538 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CC-93538. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

CC-93538

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Eosinophilic Esophagitis2 trials

Atopic Dermatitis1 trial

Concentration1 trial

Gastroenteritis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News